Alafair Rises in Inc. 5000 Rankings as Growth Accelerates Ahead of VersaCoat™ Flowable Hydrogel Launch
AUSTIN, Texas, Aug. 14, 2025 /PRNewswire/ — Alafair Biosciences, a medical device company redefining soft-tissue protection in orthopedic surgery, announced today that it moved up 254 spots to No. 574 on the 2025 Inc. 5000 List, Inc.’s annual ranking of the fastest-growing private companies in America. This prestigious ranking list provides a data-driven look at the most successful companies and places Alafair in the top 11% of this year’s honorees.
“Climbing the Inc. 5000 list is a proud moment for Alafair and a testament to the hard work, dedication, and innovation that fuel our growth every day,” said John Joyoprayitno, President & CEO of Alafair Biosciences. “That same spirit is driving our upcoming launch of VersaCoat™ Flowable Hydrogel, advancing our mission to address post-operative scarring and improve patient recovery. This recognition reflects not only our business growth, but also the expansion of our product portfolio, advancing solutions that support surgeons and transform patient care.”
This year’s Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. The top 500 companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years.
Building on its proprietary technology platform, Alafair Biosciences recently announced that it has received two 510(k) clearances from the FDA for VersaCoat™ Tendon Protector and VersaCoat™ Nerve Protector, marketed as a single product, VersaCoat Flowable Hydrogel. VersaCoat Flowable Hydrogel is a syringe-deliverable gel that provides a protective, gliding interface designed to limit post-operative tethering of soft tissues, such as tendons, ligaments, skeletal muscles, and peripheral nerves, in patients of all ages.
For the full list, company profiles, and a searchable database by industry and location, visit: www.inc.com/inc5000.
About Alafair Biosciences, Inc.
Alafair Biosciences is a privately held medical device company developing and marketing an innovative product portfolio based on its proprietary hydrogel technology. Alafair’s mission is to revolutionize surgical care with our versatile hydrogel technology, delivering unparalleled value to patients, surgeons, and healthcare facilities by enhancing soft tissue protection and by elevating patient outcomes. Alafair products are distributed through a dispersed network of independent distributors across the United States.
About VersaCoat™ Flowable Hydrogel
VersaCoat Flowable Hydrogel (VersaCoat Tendon Protector, VersaCoat Nerve Protector) is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement. VersaCoat Tendon Protector is indicated to manage and protect injured tendons where there is no substantial loss of tendon tissue, to manage and protect surrounding tissues such as ligaments and skeletal muscles, and may encounter structures such as anchors, grafts, staples, and sutures. VersaCoat Nerve Protector is indicated to manage peripheral nerve injuries where there is no substantial loss of nerve tissue. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes. The gel form is designed to delicately deliver precise volumes onto complex geometries that are difficult to visualize or reach.
About VersaWrap® Hydrogel Sheet
VersaWrap Hydrogel Sheet (VersaWrap Tendon Protector, VersaWrap Nerve Protector) is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement. VersaWrap Tendon Protector is indicated to manage and protect injured tendons where there is no substantial loss of tendon tissue, to manage and protect surrounding tissues such as ligaments and skeletal muscles, and may encounter structures such as anchors, grafts, staples, and sutures. VersaWrap Nerve Protector is indicated to manage peripheral nerve injuries where there is no substantial loss of nerve tissue. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes. The sheet form is designed to easily apply an ultrathin, uniform layer or to circumferentially wrap injured tissue.
SOURCE Alafair Biosciences, Inc.
The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…
Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…
The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…
MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…
NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…